VOGLIBITE M (Metformin (500mg) + Voglibose (0.3mg))

Voglibite-M 0.3 Tablet is categorized as an anti-diabetic medication utilized primarily for managing type 2 diabetes mellitus in adults. This formulation combines multiple agents aimed at aiding in the maintenance of appropriate blood glucose levels for those diagnosed with diabetes. It is essential to administer the tablet alongside food to enhance absorption and effect. Consistency in timing is crucial; taking it at the same hour each day maximizes its efficacy. The prescribing physician will determine the ideal dosage for you, which may need periodic adjustments based on your blood glucose monitoring results. Continuation of this medication is important, even if you experience a sense of well-being or stable blood sugar levels, as abrupt discontinuation can lead to increased glucose levels, heightening the risk of severe complications such as renal dysfunction, visual impairment, neuropathy, or loss of extremities. It is important to remember that this treatment is just one facet of a comprehensive diabetes management strategy that also emphasizes a balanced diet, physical activity, and weight management as recommended by your healthcare provider. Your lifestyle choices significantly influence the effectiveness of diabetes control. While using this medication, you may encounter mild side effects like nausea, altered taste perception, decreased appetite, gas, abdominal discomfort, diarrhea, or skin rashes, which are typically temporary and should resolve with time. Should these issues persist or escalate, it is advisable to consult your healthcare provider for potential solutions or interventions. Caution is advised for individuals with type 1 diabetes, diabetic ketoacidosis, or significant renal or hepatic impairment. Prior to initiation, inform your physician of any history of cardiac conditions. Pregnant and nursing women are encouraged to seek medical guidance before proceeding with this medication. Regular monitoring of blood sugar levels and potentially routine blood tests to evaluate blood cell counts and liver function is recommended during treatment.